Savara Inc. Reports Q1 Financial Results
Savara Inc. (NASDAQ:SVRA) reported a first-quarter EPS of -$0.15, missing the consensus estimate by $0.01. The company ended the quarter with approximately $203 million in cash and anticipates up to an additional $150 million through non-dilutive funding if MOLBREEVI receives approval.
Tickers: $SVRA
Topics: biopharmaceutical clinical-stage company rare diseases